These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Testis cancer: some problems still remain unsolved. Albers P; Bokemeyer C World J Urol; 2017 Aug; 35(8):1159-1160. PubMed ID: 28509970 [No Abstract] [Full Text] [Related]
4. Germ-cell tumors of the testis: improved results in a prospective study using combined modality therapy and biochemical tumor markers. Scardino PT; Skinner DG Surgery; 1979 Jul; 86(1):86-93. PubMed ID: 88077 [No Abstract] [Full Text] [Related]
5. [Chemotherapeutic treatment regimens for germinal testicular tumors]. Hofmann W; Langkopf B; Heinrichs HJ; Rebmann U Z Urol Nephrol; 1983 Nov; 76(11):741-50. PubMed ID: 6320553 [No Abstract] [Full Text] [Related]
6. [The role of chemotherapy in the treatment of testicular cancer with the exception of seminomas]. Kenis Y; Piccart M; Beer M Rev Med Brux; 1983 Apr; 4(4):219-23. PubMed ID: 6192477 [No Abstract] [Full Text] [Related]
7. Molecular targets for the treatment of testicular germ cell tumors. Chieffi P Mini Rev Med Chem; 2007 Jul; 7(7):755-9. PubMed ID: 17627586 [TBL] [Abstract][Full Text] [Related]
8. Current knowledge of risk factors for testicular germ cell tumors. Fukawa T; Kanayama HO Int J Urol; 2018 Apr; 25(4):337-344. PubMed ID: 29345008 [TBL] [Abstract][Full Text] [Related]
9. Understanding the somatic-type malignant differentiation in male germ-cell cancer: a work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008;26:595-9. Necchi A; Nicolai N; Colecchia M; Salvioni R Urol Oncol; 2009; 27(2):218; author reply 218-9. PubMed ID: 19285238 [No Abstract] [Full Text] [Related]
10. Molecular characterization of testicular germ cell tumors: chasing the underlying pathways. Chovanec M; Cheng L Future Oncol; 2019 Jan; 15(3):227-229. PubMed ID: 30523697 [No Abstract] [Full Text] [Related]
11. Selected use of aggressive adjuvant chemotherapy in resected stage II nonseminomatous germ cell tumors of the testis. Pizzocaro G Prog Clin Biol Res; 1985; 203():585-90. PubMed ID: 2421344 [No Abstract] [Full Text] [Related]
12. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Powles T; Shamash J; Berney D; Oliver RT Br J Cancer; 2003 Sep; 89(6):1140-1; author reply 1141-2. PubMed ID: 12966438 [No Abstract] [Full Text] [Related]
13. Third-line chemotherapy and novel agents for metastatic germ cell tumors. Veenstra CM; Vaughn DJ Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610 [TBL] [Abstract][Full Text] [Related]
14. [Prolonged regression of metastatic tumors of the testis: rejections on prognosis]. Gayet R; Cabanne F; Guerrin J J Urol Nephrol (Paris); 1976; 82(10-11):913-6. PubMed ID: 187807 [No Abstract] [Full Text] [Related]